Summary
Ranbaxy is slowly but surely on the recovery path.
After facing every imaginable problem, they are emerging out of them 1 by 1.
Glycopyrrolate tabs mainly used for Peptic ulcer is good opportunity for Ranbaxy considering the ever increasing instances in US.
Analysis
After change in management, it is difficult to turn around a company as big as Ranbaxy.
The Japanese way of doing things is slowly inflitrating the Ranbaxy culture and we will see thing improving shortly.
Adding USD 10 - 15 million in the medium term from this product approval is very much possible for Ranbaxy.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
